Cancer Diagnostic Collaboration and Licensing Deals 2016-2024


Cancer Diagnostic Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer diagnostic deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 846 cancer diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer diagnostic dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2016.

Chapter 3 provides an overview of the leading cancer diagnostic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse cancer diagnostic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Cancer Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Diagnostic Collaboration and Licensing Deals includes:
•    Trends in cancer diagnostic dealmaking in the biopharma industry
•    Directory of cancer diagnostic deal records covering pharmaceutical and biotechnology
•    The leading cancer diagnostic deals by value
•    Most active cancer diagnostic licensing dealmakers

Cancer Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse cancer diagnostic collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in cancer diagnostic dealmaking
2.1. Introduction
2.2. Cancer diagnostic deals over the years
2.3. Most active cancer diagnostic dealmakers
2.4. Cancer diagnostic deals by deal type
2.5. Cancer diagnostic deals by therapy area
2.6. Cancer diagnostic deals by industry sector
2.7. Deal terms for cancer diagnostic deals
2.7.1 Cancer diagnostic deals headline values
2.7.2 Cancer diagnostic deal upfront payments
2.7.3 Cancer diagnostic deal milestone payments
2.7.4 Cancer diagnostic royalty rates

Chapter 3 – Leading cancer diagnostic deals
3.1. Introduction
3.2. Top cancer diagnostic deals by value

Chapter 4 – Most active cancer diagnostic dealmakers
4.1. Introduction
4.2. Most active cancer diagnostic dealmakers
4.3. Most active cancer diagnostic deals company profiles

Chapter 5 – Cancer diagnostic contracts dealmaking directory
5.1. Introduction
5.2. Cancer diagnostic contracts dealmaking directory

Chapter 6 – Cancer diagnostic dealmaking by technology type

Deal directory

Deal directory – Cancer diagnostic deals by company A-Z
Deal directory – Cancer diagnostic deals by deal type
Deal directory – Cancer diagnostic deals by therapy area

Deal type definitions

About Biopharma Research Ltd    
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Cancer diagnostic deals since 2016
Figure 2: Active cancer diagnostic dealmaking activity – 2016 - 2024
Figure 3: Cancer diagnostic deals by deal type since 2016
Figure 4: Cancer diagnostic deals by therapy area since 2016
Figure 5: Cancer diagnostic deals by industry sector since 2016
Figure 6: Cancer diagnostic deals with a headline value
Figure 7: Cancer diagnostic deals with an upfront value
Figure 8: Cancer diagnostic deals with a milestone value
Figure 9: Cancer diagnostic deals with a royalty rate value
Figure 10: Top cancer diagnostic deals by value since 2016
Figure 11: Most active cancer diagnostic dealmakers 2016 - 2024
Figure 12: Cancer diagnostic deals by technology type since 2016


Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted PDF)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2cureX, 3B Pharmaceuticals, 4bases, 4D Path, 1717 Life Science Ventures, A2 Biotherapeutics, A3P Biomedical, Abbisko Therapeutics, Abbott Laboratories, Abbvie, Abcam, Abramson Cancer Center, ABX, Academic Breast Cancer Consortium, Accudata Systems, Accuray, AccuStem Sciences, Acibadem University, Acoustic MedSystems, Acrivon Therapeutics, Adaptive Biotechnologies, Adaptive Research, ADC Therapeutics, Advanced Accelerator Applications, Advanced Nuclear Medicine Ingredients, Agena Bioscience, Agendia, Agilent Technologies, Agios Pharmaceuticals, Aidence, Aidoc, Akoya Biosciences, Alberta Health Services, Alibaba Health, Allarity Therapeutics, Allelica, Allogene Therapeutics, Almac Diagnostics, Almac Group, Alphageneron Pharmaceuticals, Alverno Clinical Laboratories, Ambry Genetics, American Health Imaging, Amgen, Amoy Diagnostics, AnchorDx, Angle, AnHeart Therapeutics, Anixa Biosciences, Anpac Bio-Medical Science, Antisoma Therapeutics, Apollomics, Applied DNA Sciences, ArcherDX, Arizona State University, AroCell, Arquer Diagnostics, ArteraAI, Artidis, Artios Pharma, ARTMS Product, Arvinas, Ashion Analytics, Asieris MediTech, Asieris Pharmaceuticals, Assistance Publique-Hôpitaux de Paris, Astellas Pharma, AstraZeneca, Astrin Biosciences, Atlas Antibodies, Atrin Pharmaceuticals, AVEO Oncology, Avera Health, Avrobio, Axela, Aytu BioPharma, BAMF Health, Bayer, Baylor Scott and White Research Institute, BC Cancer Agency, Becton Dickinson, BeiGene, Beijing Genomics Institute (BGI), Berkeley Lights, Berry Oncology, Bethyl Laboratories, Beyondspring Pharmaceuticals, BGI, BGN Technologies, Bicycle Therapeutics, Bio-Rad Laboratories, bioAffinity Technologies, BioAgilytix, Biocare Medical, Biocartis, Biocept, BioCheetah, Biocodices, Biodesix, Biofidelity, BioGemex, Biogenar, Biognosys, BioInvent, BioLizard, Biological Dynamics, BioMark Diagnostics, BioMarker Strategies, BioNano Genomics, BioNTech, BioSkryb, BioVolume, Bioyong, Bird Foundation, BL&H, Blackford, Bliss Biopharmaceutical, Blu Biotech, Blue Cross Blue Shield Association, Blue Earth Diagnostics, Blueprint Medicines, Boehringer Ingelheim, Boreal Genomics, BostonGene, Bot Image, BPGbio, Bpifrance, Bracco Imaging, Brainomix, Brazlex Medical Genetics, Breath Diagnostics, Brenus Pharma, BriaCell Therapeutics, Brigham and Women's Hospital, BrightPath Biotherapeutics, Bristol-Myers Squibb, Bristol-Myers Squibb Pakistan, Broad Institute, Bruker, Burning Rock, C2i Genomics, Cadila Pharmaceuticals, Calviri, Calyx, Cambridge Epigenetix, Canadian Cancer Society, Canadian Institutes of Health Research, CANbridge Pharmaceuticals, Cancer Research Institute, Cancer Research UK, Cancer Targeted Technology, CancerX initiative, Capsulomics, Cardiff University, Carestream Health, Caris Life Sciences, Case Western Reserve University, Castle Biosciences, CeGaT, Celcuity, Celgene, Cellgen Diagnostics, CellMax Life, Cellpath, CellSight Technologies, Celsee, Celsius Therapeutics, Centogene, Centre for Imaging Technology Commercialization, Centre for Probe Development and Commercialization, Centre Leon Berard, Cepheid, Cerba HealthCare, Certis Oncology Solutions, Champalimaud Foundation, Champions Oncology, Charles River Laboratories, Children's Hospital Boston, Children's Hospital Los Angeles, Children's Hospital of Orange County, China Grand Pharma, China Grand Pharmaceutical, Chinese University of Hong Kong, Christian Doppler Research Association, ChromaCode, Chronix Biomedical, Chugai Pharmaceutical, City of Hope, Cizzle Biotech, CK Life Sciences, Clarity Pharmaceuticals, Clarix, Clearbridge Biomedics, ClearLight Diagnostics, ClearNote Health, Cleveland Clinic, Cleveland Diagnostics, Cleveland University Hospitals, Clinical Genomics, Clinical Laserthermia Systems (CLS), CloudHealth Genomics, Clovis Oncology, Co-Diagnostics, Coeptis Pharmaceuticals, Cofactor Genomics, Colorado Melanoma Foundation, Colorado State University, Columbia University, Columbia University Medical Center, ConcertAI, Congenica, Contextual Genomics, Copenhagen University Hospital, CoreBiome, CorePath Laboratories, CorePlus, Cornell University, Criterium, Crosscope, CSI Laboratories, CStone Pharmaceuticals, Culmination Bio, Curasight, CureMetrix, Curium, Curta, Cypre, Cytogen, Daiichi Sankyo, Dako, Dana-Farber Cancer Institute, Danish Center for Strategic Research into Type 2 Diabetes, DaRui Biotech, DarwinHealth, Day One Biopharmaceuticals, Debiopharm, Decipher Biosciences, deCODE Genetics, Deep Bio, Deepcell, Delphi Diagnostics, Dendreon, Denovo Biopharma, Densitas, Department of Defense, Devyser Diagnostics, DiaCarta, DIAN Diagnostics, Diannei Biotechnology, Diaprost, Diatech Pharmacogenetics, DNAmito, DoMore Diagnostics, DuChemBio, Duke University, Duke University Medical Center, Dxcover, DxTerity, DYNEX Technologies, Early is Good, EchelonDx, Eckert & Ziegler, Edico Genome, Edinburgh Molecular Imaging, EDP Biotech, EDX Medical, Eigen, Eisai, Elephas, Elevation Oncology, Eli Lilly, EmeritusDX, Emit Imaging, Emory University, Endoluxe, Enigma Biomedical, Enterome Bioscience, Epic Sciences, Epiphany Dermatology, Epizyme, Erasmus University Medical Center, ESSA Pharma, Essen University Hospital, Euformatics, Eureka Eurostars, European Commission, European Innovation Council, European Institute of Oncology (EIO), European Organization for Research and Treatment of Cancer, Exact Sciences, Exai Bio, Exigent Research, EXINI Diagnostics, Exosome Diagnostics, Exosome Sciences, F-Star Therapeutics, Factorial Diagnostics, Falco, Farcast Biosciences, Ferronova, Ferrum Health, Fibrogen, FivepHusion, Five Prime Therapeutics, Flagship Biosciences, Flare Therapeutics, Flatiron Health, Florida Theranostics, FLX Bio, Focal Healthcare, Fondation Cancer, Fondatioun Kriibskrank Kanner, Foresight Diagnostics, Fortis Therapeutics, Foundation Medicine, Fox Chase Cancer Center, Francis Crick Institute, Fred Hutchinson Cancer Research Center, Freenome, Friends of Cancer Research, Fudan University, Fujifilm medical systems, Fujirebio Diagnostics, Fulgent Genetics, Fuzionaire Diagnostics, Fuzionaire Radioisotope Technologies, GANZIMMUN Diagnostics, GBI BioManufacturing, GC Genome, GE Healthcare, GeneCentric Therapeutics, GeneNews, Genentech, GeneQuantum Healthcare, Geneseeq, GenesisCare, Genetic Technologies, Genetron Health, Genmab, Genome Canada, Genome Diagnostics, GenomeDx, Genomic Health, Genomics England, Genomic Testing Cooperative, Genomill Health, Genomoncology, Genoptix, Georgetown University, German Cancer Research Center, German Federal Ministry of Education and Research, Gestalt Diagnostics, Gibson Oncology, Gilead Sciences, Global Lung Cancer Coalition, GNS Healthcare, Google, Government of Canada, Grail, Gritstone Bio, GSK, Guardant Health, Guerbet, Guided Therapeutics, Gyros Protein Technologies, Hainan Sinotau Pharmaceutical, HalioDx, Halo Dx, HALO Precision Diagnostics, Harbinger Health, Harvard Medical School, Harvard University, Haystack Oncology, HealthCare Konnect, Hebrew University of Jerusalem, Heidelberg Pharma, Helio Genomics, Helio Health, Helomics, Henan Cancer Hospital, Hengrui Therapeutics, Henlius Biotech, Henry M. Jackson Foundation, Heska, HiberCell, HiloProbe, Hitachi, Hitachi Medical Systems Europe, Hoag Memorial Hospital Presbyterian, Holobeam Technologies, Hologic, Horizon Discovery, Horizon Europe, Hospital Clinic of Barcelona, HotSpot Therapeutics, HTG Molecular Diagnostics, Huma, Hummingbird Bioscience, Huntsman Cancer Institute, Hybridyne Imaging Technologies, Ibex Medical Analytics, IBM, IBM Watson Health, iCAD, Icahn School of Medicine at Mount Sinai, ICAN, Idaho Urologic Institute, Idengene, Ikonisys, Ikonopedia, Illumina, Image Analysis, ImaginAb, Imaging Associates, Imanis Life Sciences, IMBdx, ImmunID Technologies, Immunovia, IMPACT Therapeutics, Imperial College London, IncellDx, Incyte, Indiana University, Indica Labs, Indivumed, Industrial Centre for Artificial Intelligence Research in Digital Diagnostics, Inflammatory Breast Cancer Research Foundation, Inform Diagnostics, Inivata, Innoplexus, Innovate BC, Innovate UK, Inovio Pharmaceuticals, InSightec, InSphero, Institut Català d'Oncologia, Institut Curie, Institute for Bioscience and Biotechnology Research, Institute of Cancer Research, Institut Gustave Roussy, Institut Paoli-Calmettes, Integrated Biobank of Luxembourg, Integrated DNA Technologies, Intermountain Healthcare, International Association for the Study of Lung Cancer, International Centers for Precision Oncology Foundation, Interpace Diagnostics, Intezyne, Invenio Imaging, inviCRO, Invitae, InVivoScribe, ION Solutions, IRX Therapeutics, Isotopia Molecular Imaging, Item, ITM Isotopen Technologien, Janssen-Cilag, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Jefferson Healthcare, Jiangsu Chia Tai Tianqing Pharmaceutical, Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, John Wayne Cancer Institute, Juno Therapeutics, Juntendo University, Kailos Genetics, Kanazawa University, Karolinska University Hospital, Kartos Therapeutics, Karyopharm Therapeutics, KDx Diagnostics, Kephera Diagnostics, KEW, Kheiron Medical Technologies, Kite Pharma, Kiyatec, Knight Cancer Institute, Korea Pharma, Kronos Bio, Kura Oncology, Labcyte, Laboratory Corporation of America, Lantern Pharma, Lantheus Holding, Lantheus Medical Imaging, Latvian Institute of Organic Synthesis, Lawson Health Research Institute, Leap Therapeutics, Leica Biosystems, Leicester University, LEO Pharma, Les Laboratoires Servier, Leucid Bio, Lexent Bio, LifeLabs Medical Laboratory Services, LifeOmic, Life Raft Group, LifeSensors, LifeX Ventures, Lightpoint Medical, Li Ka Shing Foundation, LineaRx, Liquid Biosciences, Little Warrior Foundation, Loxo Oncology, Lucence, Lucid Diagnostics, Lumicell, Luminex, Lunaphore, Lung Cancer Initiative, Lunit, Lurie Children's Hospital of Chicago, Magic Leap, Magle Chemoswed, Magnetic Insight, Mainz Biomed, Mammoth Biosciences, Manhattan Scientifics, MapKure, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mauna Kea Technologies, Max Planck Institute for Multidisciplinary Sciences, Mayo Clinic, McMaster University, MD Anderson Cancer Center, MDNA Life Sciences, MDxHealth, Medexus Pharmaceuticals, med fusion, Medial EarlySign, MEDIAN Technologies, Medical University of Graz, Medidata Solutions, Medipath, Mediso, Medivation, medPhoton, Melanoma Research Alliance, Memorial Sloan Kettering Cancer Center, Merck and Co, Merck KGaA, Merrimack Pharmaceuticals, Metabiomics, Metabolon, Metafora Biosystems, Mevion Medical Systems, MGI Tech, Michelson Center, Microsoft, Mie University, Milburn Foundation, MindPeak, Minerva Imaging, MIODx, Mirati Therapeutics, miR Scientific, MiRXES, MITRO Biotech, Moderna, Molecular Health, Molecular Targeting Technologies, Monoceros Biosystems, Morphotek, Mount Sinai Health System, Mount Sinai Services, MP Group, mProbe Laboratories, MRI Interventions, MRM Proteomics, MSD, Multimmune, Munich Leukemia Laboratory, Munich Technical University, Myelopro Diagnostics and Research, Myriad Genetics, Nano-X Imaging, NanoMab Technology, Nanostics Precision Health, NanoString Technologies, NantHealth, NantWorks, Natera, National Cancer Center, National Cancer Center of Japan, National Cancer Centre Singapore, National Cancer Institute, National Cancer Institute of Mexico, National Institutes of Health, National Institutes of Health Clinical Center, National Organization for Rare Disorders, National Physical Laboratory, National Taiwan University Hospital, Naval Medical Research Center, Naveris, Navidea Biopharmaceuticals, Nektar Therapeutics, NeoDynamics, Neogap Therapeutics, Neogenomics, Neosoma, NeraCare, Neuvogen, New Horizon Health, New Jersey Urology, NewStem, New York University, NGeneBio, Nico, Nihon Medi-Physics, Nippon Kayaku, Nonacus, Norgine, Noria Therapeutics, Northeastern University, Northwestern University, Notable Labs, NovAliX, Novarad, Novartis, NovaScan, NovellusDx, Novigenix, Novogene, NRG Oncology, nRichDX, NTT Data, Nucleai, Nucleix, Nuclidium, NueHealth, NuProbe, NX Development, NYU Langone Medical Center, Ochin, Ohio State University, Olink Proteomics, OmiCure, Oncidium Foundation, Oncimmune, OncoAssure, OncoCyte, OncoDNA, OncoGenesis, Oncoheroes Biosciences, OncoHost, Oncology Venture, OncoNano Medicine, OncoTracker, Oncovet, OncXerna Therapeutics, OnLume Surgical, Ono Pharmaceutical, Onsite Women’s Health, Ontario Institute for Cancer Research, Optellum, OracleBio, Oregon Health Sciences University, OrigiMed, Osaka University, OSE Immunotherapeutics, Oslo University Hospital, Ospedale Pediatrico Bambino Gesu, Owkin, Owlstone Medical, Oxford Nanopore Technologies, Pacific Biosciences, Paige, Panacea Pharmaceuticals, Pancreatic Cancer Early Detection Consortium, Paradigm, Parthenon Therapeutics, PathAI, PathGroup, Pathnova Laboratories, PathPresenter, Paul Scherrer Institute, PAVmed, Pennsylvania State University, PentixaPharm, Pepscan, Personal Genome Diagnostics, Personalis, Pfizer, Pfizer Canada, PharmaLogic, PHC, PhenoVista Biosciences, Philips, Phillips-Medisize, Philochem, Phoenix Molecular Designs, Photocure ASA, Phytronix Technologies, PierianDx, Pierre Fabre, Pillar Biosciences, Pionyr Immunotherapeutics, PixCell Medical, Planet Innovation, Planmed, Plus Therapeutics, Point32Health, POINT Biopharma, Polarean Imaging, Precipio Diagnostics, PreciseDx, Precision for Medicine, Precision Pathology Services, Predicine, Predictive Technology Group, PrediLife, Premier Inc, PreMIT, Prenetics, Preora Diagnostics, Prescient Medical, Previse, Progenics Pharmaceuticals, Promega, ProPath, Prophase Labs, Proscia, Protea Biosciences, Protean BioDiagnostics, ProteoMediX, Providence Saint John's Health Center, PSI CRO, PT Elion Medika, Puerto Rico Government, Puma Biotechnology, Purdue Research Foundation, QED Therapeutics, Qiagen, Qlarity Imaging, QT Imaging, Qualigen, Quanterix, Quantum Leap Health Care Collaborative, Quebec Heart and Lung Institute, Queensland University of Technology, Queens University Belfast, Quest Diagnostics, Qure Healthcare, R-Pharm, Race Oncology, Radboud University Nijmegen Medical Centre, Radiomedix, Radiopharm Theranostics, Radius Health, RadNet, Rarecells, Ratio Therapeutics, RAW, RayBiotech, Realm IDx, RefleXion Medical, Relay Therapeutics, Renji Hospital, Renown Institute for Health Innovation, Research Center for Molecular Medicine of the Austrian Academy of Sciences, Resolution Bioscience, RevealDx, Reveal Genomics, RiboMed, Roche, Roche Diagnostics, Roche Molecular Systems, Rosetta Genomics, Roswell Park Cancer Institute, ROTOP Pharmaka, Royal Marsden Hospital, Royal Philips Electronics, Rubix LS, Rutgers Cancer Institute of New Jersey, SAGA Diagnostics, Saladax Biomedical, Sanofi, Sarah Cannon Research Institute, Satisfai Health, Sayre Therapeutics, Scandion Oncology, SciBase, Scienion, Scintomics, Screenpoint Medical, Seattle Children's Hospital, Sebela Pharmaceuticals, Sebia, Secarna Pharmaceuticals, Seegene, SeekIn, Selexis, Sengenics, SEngine Precision Medicine, Seracare Life Sciences, Shanghai Pharmaceutical, Sheba Medical Center, Shenzhen Chipscreen Biosciences, Sherlock Biosciences, Shuttle Pharmaceuticals, Shuwen Biotech, Siemens Healthineers, Signet Medical Solutions, SimBioSys, Simsen Diagnostics, Singlera Genomics, Sirona Medical, Sirtex Medical, Skane University Hospital, Skyline Diagnostics, SkylineDX, Skysong Innovations, Smilow Cancer Hospital at Yale-New Haven (SCH), Smiths Medical, Sofie Biosciences, Solis Mammography, SomaLogic, Sona Nanotech, Sonic Healthcare, Sonrai Analytics, SOPHiA Genetics, Soricimed Biopharma, SOTERIA Precision Medicine Foundation, Spectrum Pharmaceuticals, Spectrum Solutions, Spesana, Sphingotec, SST Group, St. Jude Children's Research Hospital, Stanford University, Stanford University School of Medicine, Starpharma, Statera Biopharma, Strata Oncology, Stratasys, STRATIFYER Molecular Pathology, Sunnybrook Research Institute, Surrey Cancer Research Institute, Susan G. Komen for the Cure, Swift Biosciences, Swiss Institute of Allergy and Asthma Research, Swiss Institute of Bioinformatics (SIB), Synaptive Medical, Sysmex, Sysmex Inostics, T-Cure Bioscience, TaiRx, Take2, Takeda Pharmaceutical, Tampere University Hospital, Tasly Pharmaceuticals, Techcyte, Tel Aviv University, TeleMammography Specialists, Telix Pharmaceuticals, Telo Genomics, Tempus, TeraRecon, Texas A&M University, The Parker Institute For Cancer Immunotherapy, Theragnostics, Theralink Technologies, TheraPanacea, Therapixel, Thermo Fisher Scientific, The Technical University Of Munich, ThinkCyte, Thomas Jefferson University, Threshold Pharmaceuticals, TME Research, Tocagen, Todos Medical, Tor Vergata University Hospital, TP Therapeutics, Transcenta, TransCode Therapeutics, Transgenomic, TriSalus Life Sciences, TrovaGene, TScan Therapeutics, TumorGen, Turgut Ilaclari, Twist Bioscience, Tymora Analytical Operations, uBiome, UK Government, Ultivue, Unilabs, Uni Targeting Research, Universal DX, University Ann & Robert H. Lurie Children’s Hospital, University College London, University Health Network, University Hospital Bispebjerg, University Hospital of Leuven, University Medical Center Hamburg-Eppendorf, University of Antwerp, University of Arizona, University of Arkansas, University of Augsburg, University of Barcelona, University of Birmingham, University of Bonn, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Florida, University of Greifswald, University of Heidelberg, University of Illinois, University of Lausanne, University of Leeds, University of Louisville, University of Manchester, University of Massachusetts Medical School, University of Melbourne, University of Miami, University of Michigan, University of Milano-Bicocca, University of Minnesota, University of Newcastle, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rostock, University of Sheffield, University of Southampton, University of South Carolina, University of Sunderland, University of Surrey, University of Texas Health SCience Center at San Antonio, University of Texas Southwestern Medical Center, University of Virginia, University of Washington, UPMC, Urology Centers of Alabama, Urology San Antonio, UroPartners, UroViu, USC Norris Comprehensive Cancer Center, US Oncology, US Radiology Specialists, Varian Medical Systems, Vect-Horus, Vela Diagnostics, Ventana Medical Systems, Veracyte, Verily, Viatar CTC Solutions, Vida Diagnostics, Vidence, ViennaLab Diagnostics, Viewpoint Molecular Targeting, Vincere Cancer Center, Virginia Tech Intellectual Properties, Visiopharm, VolitionRX, Volpara Solutions, VyGen-Bio, Vyriad, Wallace H. Coulter Foundation, Waseda University, Washington University in St Louis, Watchmaker Genomics, Weihai Weigao Medical Devices, Weill Cornell Medical College, Weizmann Institute, WellDyne, Wellmarker Bio, West German Study Group, Whiterabbit, Whitman-Walker Institute, Wilex, Windber Research Institute, WuXi NextCODE Genomics, Wyss Institute, Xencor, Xiamen Encheng Group, XtalPi, Xylonix, Yale School of Medicine, Yale University, Yemaachi Biotech, Yitu Medical, York Instruments, ZAI Laboratory, Zealand University Hospital, Zomedica, zPREDICTA

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!